Abstract
Guardant Health Inc. will report third-quarter results on November 05, 2026 Post-Mkt; this preview summarizes last quarter’s actuals, this quarter’s sell-side and company-level forecasts, and the major themes likely to influence the print and the stock reaction.
Market Forecast
Consensus points to revenue of 350.36 million US dollars for the current quarter, up 48.65% year over year, with forecast EBIT at -53.25 million US dollars and EPS at -0.32, implying continued operating-loss moderation; YoY growth inputs are interpreted as ratios, indicating EPS improvement of 55.02% and EBIT improvement of 47.54%. Margin color from recent quarters suggests gross profit margin around the mid-60s and a gradually improving net loss margin; adjusted EPS is expected to narrow significantly year over year. The company’s core testing operations are expected to expand at a healthy clip as clinical adoption broadens and biopharma programs deepen. Screening is highlighted by forecasters as a key growth engine given expanding payer coverage and guideline support, with segment revenue scale-up from the prior quarter’s 52.87 million US dollars and a high double-digit YoY trajectory.
Last Quarter Review
Guardant Health Inc. reported last quarter revenue of 344.98 million US dollars, gross profit margin of 65.39%, net profit attributable to shareholders of -120.00 million US dollars with a net profit margin of -35.87%, and adjusted EPS of -0.42, reflecting a 48.64% year-over-year revenue increase and a 47.50% improvement in adjusted EPS. One notable highlight was the sizable top-line beat versus consensus, indicating robust test volume growth and resilience in biopharma partnership revenue. By business line, oncology testing contributed 219.11 million US dollars, biopharma and data contributed 60.95 million US dollars, screening delivered 52.87 million US dollars, and licensing and other contributed 2.06 million US dollars, underscoring oncology as the largest revenue base and screening as the fastest scaler.
Current Quarter Outlook
Main testing business
The central engine remains the oncology testing franchise, which accounted for 219.11 million US dollars last quarter. Momentum here tends to track physician adoption, payer coverage expansion, and menu breadth in both tissue and liquid biopsy offerings. With forecast revenue growth of 48.65% year over year this quarter, the setup implies continued demand across therapy selection and monitoring tests. Margins are expected to benefit from scale and operating efficiency gains as high-throughput infrastructure absorbs rising volumes, though mix shifts toward earlier-stage testing and new product launches can create transient gross margin variability. Investors will watch order momentum and reimbursement trends to gauge the sustainability of mid-60s gross margin and the pace of operating loss reduction.
Most promising growth vector: Screening
Screening delivered 52.87 million US dollars last quarter and remains the company’s highest potential growth vector in terms of absolute market size. The forecast framework implies that screening should outgrow the corporate average as payer adoption improves and as clinical data matures, supporting broader guideline inclusion and primary care awareness. The financial implication is two-fold: accelerated revenue scaling and a path to structural cost leverage as fixed lab costs are spread across larger volumes. Key print-day variables include screening order growth rates, reported payor coverage milestones, and any color on conversion from pilots to routine use. Any improvement in per-test reimbursement and contracting could flow through to both gross margin stability and EBIT improvement beyond the current -53.25 million US dollars estimate.
Stock-price drivers this quarter
Three items are likely to dominate the share reaction. First, the magnitude of the revenue beat or miss versus the 350.36 million US dollars consensus, given last quarter’s sizable top-line surprise, will shape sentiment on demand durability. Second, profitability trends will be in focus: the Street is modeling EPS at -0.32 and EBIT at -53.25 million US dollars, implying another step toward narrowing losses; any incremental operating-expense discipline or gross margin outperformance would strengthen the path to breakeven. Third, segment commentary—particularly on screening adoption and biopharma activity—will guide medium-term growth expectations; confirmation of order acceleration, contract wins, or guideline catalysts typically commands a premium, while delays or mix pressure could temper the multiple.
Analyst Opinions
The majority of recent analyst commentary trends constructive, emphasizing accelerating revenue growth and improving loss metrics into the November 05, 2026 print, with most framing expectations as beatable on revenue and in line to modestly better on EPS. Cited reasoning includes continued volume expansion in core oncology testing, a strengthening screening ramp, and stable-to-improving gross margin dynamics. Representative sell-side voices highlight risk-reward skew from operational leverage and coverage expansion, while acknowledging execution and reimbursement risks; the balance of views is cautiously bullish, with a minority flagging potential volatility if screening growth proves uneven or if expense timing offsets revenue upside.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments